IPP Bureau
Formation Bio snaps up global rights to next-gen CNS TYK2 inhibitor from Lynk Pharma
By IPP Bureau - December 12, 2025
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
New oral SERD from Roche delivers significant survival edge in early breast cancer
By IPP Bureau - December 12, 2025
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
Lupin Manufacturing Solutions partners with PolyPeptide to scale global peptide supply chain
By IPP Bureau - December 12, 2025
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
Shilpa Medicare receives initial authorization for Rotigotine transdermal patch from Europe
By IPP Bureau - December 12, 2025
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
Granules India receives official 2025 CDP rating
By IPP Bureau - December 12, 2025
The company had achieved the highest "A" rating in Climate Change
Dr. Reddy's Laboratories announces SBTi targets
By IPP Bureau - December 12, 2025
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
Senores Pharmaceuticals launches of Deferiprone Tablets USP, 500 mg & 1000 mg
By IPP Bureau - December 12, 2025
The product will be marketed by Dr. Reddy's Laboratories Inc.
Granules Life Sciences facility receives EIR from USFDA
By IPP Bureau - December 12, 2025
This approval confirms the facility's compliance with FDA quality standards and regulatory requirements
Apitoria Pharma receives 3 observations from USFDA for Unit-V
By IPP Bureau - December 12, 2025
The company will respond to the US FDA within the stipulated timelines
Teva files FDA application for once-monthly schizophrenia injection
By IPP Bureau - December 11, 2025
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
Lilly drug cuts risk of disease progression or death by 80% in trial
By IPP Bureau - December 11, 2025
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
BioNTech and Bristol Myers Squibb report punchy early results for experimental TNBC therapy
By IPP Bureau - December 11, 2025
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Roche secures CE mark for groundbreaking Vaginitis test that promises accurate diagnosis
By IPP Bureau - December 11, 2025
Roche says its new assay “resolves this challenge by delivering accurate and specific results
Roche secures European nod for Gazyva/Gazyvaro in Lupus Nephritis patients
By IPP Bureau - December 11, 2025
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Bristol Myers Squibb unveils breakthrough Lymphoma data
By IPP Bureau - December 11, 2025
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
